Related Experiment Video
Updated: Jul 4, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Dupilumab-associated head and neck dermatitis: Rapid response with abrocitinib treatment
Adinia Santosa1, Yik Weng Yew1
1National Skin Centre Singapore Singapore.
Abstract:
Development or exacerbation of head and neck dermatitis (HN-D) in association with dupilumab has been reported. Severity of HN-D varies, and may persist even with discontinuation of dupilumab. Development or exacerbation of HN-D is not yet completely understood, and various hypotheses have been made about the possible underlying pathophysiology. To date, there is no established treatment for HN-D in association with dupilumab. We report 2 cases of HN-D occurring following dupilumab treatment, with significant improvement of HN-D following treatment with abrocitinib.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

